Clinical Data, Inc. (NASDAQ: CLDA) announced today that the United States Adopted Name Council (USAN) has approved the generic name vilazodone hydrochloride.
Popularity: 1% [?]
Related posts:
- Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder
- Clinical Data, Inc. Initiates Second Pivotal Phase III Study Of Vilazodone
- Clinical Data Initiates Long-Term Safety Study For Vilazodone
- Clinical Data Initiates Long-Term Safety Study For Vilazodone
- Actavis Receives Approval Of Generic Wellbutrin XL(R) 300mg In The United States
Comments
No Responses to “Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression”